Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to ...
China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
Nautilus Biotechnology (NASDAQ:NAUT) reported first-quarter 2026 results and highlighted progress toward its planned ...
BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform ...
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...
Zacks Investment Research on MSN
Should you invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund ...
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...
Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results